Compare
ENDRA Life Sciences Inc. vs Escalon Medical Corp vs Nuwellis, Inc. vs Neuraxis, Inc
| Latest fiscal year | ENDRA Life Sciences Inc. NDRA | Escalon Medical Corp ESMC | Nuwellis, Inc. NUWE | Neuraxis, Inc NRXS |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-06-30 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $12.05M | $8.27M | $3.57M |
| Revenue growth (YoY) | n/a | +0.5% | -5.4% | +32.9% |
| Gross margin | n/a | 45.7% (computed) | 62.0% | 84.2% |
| Operating margin | n/a | 1.1% | -134.3% | -219.4% |
| Net margin | n/a | 0.9% | -211.9% | -218.5% |
| Net income | -$7.03M | $105.5K | -$17.52M | -$7.80M |
| EPS (Diluted) | -$8.93 | $0.00 | -$25.39 | -$0.95 |
| Operating cash flow | -$5.18M | $380.7K | -$10.81M | -$6.43M |
| Free cash flow | -$5.20M | $376.8K | -$10.90M | -$6.46M |
| Cash & equivalents | n/a | $545.8K | $1.08M | $4.97M |
| Total assets | $3.85M | $4.99M | $6.12M | $6.40M |
| Total liabilities | $1.59M | $3.08M | $3.49M | $3.00M |
| Shareholders' equity | $2.26M | $1.92M | $2.62M | $3.40M |
| Return on year-end equity | -310.9% | 5.5% | -667.7% | -229.5% |
| Shares outstanding | 1.18M | 7.42M | 1.69M | 10.65M |
Revenue, most recent five fiscal years
| Fiscal year | ENDRA Life Sciences Inc. | Escalon Medical Corp | Nuwellis, Inc. | Neuraxis, Inc |
|---|---|---|---|---|
| Latest | $0 Ended 2020-12-31 | $12.05M Ended 2025-06-30 | $8.27M Ended 2025-12-31 | $3.57M Ended 2025-12-31 |
| 1 year earlier | $0 Ended 2019-12-31 | $11.98M Ended 2024-06-30 | $8.74M Ended 2024-12-31 | $2.69M Ended 2024-12-31 |
| 2 years earlier | $6.2K Ended 2018-12-31 | $12.18M Ended 2023-06-30 | $8.86M Ended 2023-12-31 | $2.46M Ended 2023-12-31 |
| 3 years earlier | $351.6K Ended 2017-12-31 | $10.70M Ended 2022-06-30 | $8.54M Ended 2022-12-31 | $2.68M Ended 2022-12-31 |
| 4 years earlier | $515.6K Ended 2016-12-31 | $10.47M Ended 2021-06-30 | $7.92M Ended 2021-12-31 | n/a |